Cannabis or CBD before anesthesia: disclose the product, route, pattern, and last use

Tell the surgeon and anesthesia clinician about every cannabis or cannabinoid product before a procedure: THC, CBD, prescribed cannabinoid medicines, flower, vapes, concentrates, edibles, drinks, tinctures, capsules, and topicals. Include route, estimated amount, frequency, purpose, last use, and other medicines. Current consensus guidance supports screening everyone and postponing elective care when acute intoxication impairs decision-making, but it does not supply one evidence-based stop interval that fits every product, pattern, patient, and anesthetic.¹²³

Legal status and medical authorization do not make the exposure irrelevant to anesthesia. Disclosure is a planning input, not a moral test.

“Cannabis use” is too vague for an anesthesia record

Photograph the package and ingredient panel when available. “One hit,” “a gummy,” and “CBD oil” are not standardized doses. Products may contain more or less THC than expected, combine cannabinoids, or include other ingredients.

The anesthesia question changes with timing and clinical signs

ASRA Pain Medicine’s consensus guideline recommends asking all preoperative patients about cannabinoid product type, time of last consumption, route, amount, and frequency. It also recommends evaluating for acute intoxication.¹ An impaired patient may be unable to provide valid informed consent or may have altered cognition and physiologic effects that change the immediate plan.

The guideline advises delaying elective surgery after recent smoking for a bounded cardiovascular interval and postponing when intoxication impairs decision-making, but it notes insufficient evidence to set a comparable duration for every nonsmoked route.¹ ASA’s patient guidance similarly emphasizes that recommendations vary with procedure and history.² The American College of Surgeons publishes broader general advice for surgery.³

Do not choose whichever public interval is shortest or longest. Ask the actual anesthesia clinician for written instructions that reconcile product, route, chronicity, symptoms, operation, anesthetic depth, other medicines, and facility policy. Do not stop a prescribed cannabinoid medicine without coordination with its prescriber and perioperative team.

Airway, circulation, anesthesia, pain, and withdrawal are different jobs

Inhaled cannabis adds smoke or aerosol exposure to the cannabinoid record. Cough, wheeze, sputum, shortness of breath, a recent respiratory illness, or a change in exercise tolerance should be disclosed; the anesthesia clinician decides how those facts affect airway planning.¹³ Edibles avoid smoke but do not avoid intoxication, delayed effects, sedation, or medicine-interaction questions.

Cannabinoids can affect heart rate and blood pressure, and acute use may matter differently from chronic use.¹ The team also considers anesthetic requirements, nausea and vomiting, postoperative pain, sedating medicine combinations, and whether frequent use could lead to withdrawal during recovery. Evidence quality varies by question, and an association in observational studies is not a dose rule for an individual.

ASRA guidance reports that frequent users may have different postoperative pain and opioid-use patterns and recommends counseling rather than assuming cannabis will substitute for a perioperative pain plan.¹ A disclosure should therefore reach both the anesthesia and recovery plan, not stop at the pre-op form.

CBD is not a single low-risk category

FDA has approved one prescription cannabidiol product for specific seizure indications. FDA also warns that nonprescription CBD products may carry unproven claims, unknown quality, potential liver effects, and drug-interaction concerns.⁴ “CBD only” therefore does not prove zero THC, zero sedation, zero systemic exposure, or zero interaction.

The relevant distinction is the exact finished product. A prescription label provides a known formulation and dose but still belongs on the medication list. A retail tincture may have a certificate of analysis, yet a batch report is not a perioperative interaction assessment. A topical cosmetic is not automatically equivalent to a transdermal system designed for systemic delivery.

Do not use the article to infer that CBD must be stopped, continued, or dose-adjusted. Provide the item and schedule to the clinicians who can reconcile it with the anesthetic and other medications.

Build the plan before the day of surgery

Many patients first meet the anesthesia professional on the procedure day. If cannabis is frequent, prescribed, hard to pause, associated with symptoms, or used with other sedating substances, ask the surgeon’s office for an earlier anesthesia contact. Waiting can turn a manageable planning question into a same-day postponement or an unsafe omission.

Request answers to five operational questions:

1. Who gives product-specific instructions—the surgeon, anesthesia clinician, prescriber, or all three?
2. What information or packaging should be brought?
3. What use, symptoms, or impairment would change timing or location?
4. How are prescribed cannabinoids, pain medicines, nausea medicines, and withdrawal addressed?
5. What are the written cancellation, deposit, and rescheduling terms if the procedure cannot proceed?

Those questions matter for office-based cosmetic surgery because the facility’s rescue capacity and transfer plan may differ from a hospital. Verify the anesthesia depth and personnel separately from the cannabinoid plan.

Recovery is not the time to improvise

Postoperative anesthetics and pain medicines can affect judgment, coordination, breathing, and alertness. ASA cautions that combining cannabis with sedating medicines can worsen impairment and notes that the safe time to resume is not established as one universal rule.² Smoking or vaping may also provoke coughing that stresses an incision.

Before discharge, the written medication plan should state who answers questions about prescribed or consumer cannabinoid use, driving, caregiver responsibilities, pain, nausea, sleep, and concerning symptoms. If cannabis was being used for a medical problem, the plan should involve the responsible prescriber rather than leaving a gap.

1. 1. Inventory the exact products. Record label, ingredients, route, amount, frequency, source, purpose, last use, and a package photo.
2. 2. Disclose early and privately. Send the information before procedure day and ask for a private conversation if companions are present.
3. 3. Reconcile the full substance list. Include prescriptions, OTC products, supplements, nicotine, alcohol, and other sedating or inhaled exposures.
4. 4. Obtain written instructions. Use the actual surgeon, anesthesiologist, and prescribing clinician; do not select a generic internet interval.
5. 5. Plan postponement and recovery. Know which symptoms or impairment change the plan, the financial terms, and who manages pain, withdrawal, and resumption questions.

The decisive question is: “Given this exact cannabinoid product, route, pattern, last use, symptoms, and medication list, what does my surgeon and anesthesia clinician need to change before, during, or after this procedure?”